NYSE · CIK 0001708599
SER Serina Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jul 23, 2026. Close $2.00 on Oct 9, 2026, +56% from the 52-week low and -64% from the high.
In brief
Serina Therapeutics, Inc. (SER) has 67 SEC Form 4 filings on file from 11 insiders, the latest filed on Jul 23, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
41 open-market trades have been scored at SER. The newest: Stephen K. Brannan (director) bought $2,030 of stock on Jul 7, 2026, filed Jul 9, 2026, scored 31 (weak). The largest of the 41 shown: Randall Moreadith (Chief Scientific Officer) sold $331k on Aug 25, 2025, scored 15 (weak), under a 10b5-1 plan. 3 insiders bought within 14 days of each other around May 22, 2026.
3 Form 144 notices of planned sales are on file, the latest filed Jan 20, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
SEROct 9, 2026 · close 2.00
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Serina Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Stephen K. Brannan director buy | $2,030 1,000 shares | - | +70% from low-64% from high | |
| 46Moderate | Jay Venkatesan director buy | $1,048 589 shares | - | +55% from low-68% from high | |
| 36Weak | Karen J Wilson director buy | $18k 10,100 shares | - | +41% from low-71% from high | |
| 52Moderate | Karen J Wilson director buy | $37k 20,000 shares | - | +47% from low-69% from high | |
| 46Moderate | Richard Peter Marshall director buy | $20k 12,183 shares | - | +26% from low-74% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $19k 6,500 shares | -100% | +146% from low-50% from high | |
| 10Weak | Randall Moreadith Chief Scientific Officer sell | $98k 39,000 shares | -100% | +94% from low-61% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $20k 6,500 shares | -100% | +42% from low-57% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $23k 6,500 shares | -100% | +42% from low-57% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $7,375 2,500 shares | -100% | +55% from low-53% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $12k 4,000 shares | -200% | +50% from low-55% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $16k 6,500 shares | -120% | +29% from low-61% from high | |
| 6Weak | Randall Moreadith Chief Scientific Officer sell | $35k 13,000 shares | -100% | +37% from low-58% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $11k 4,100 shares | -100% | 0% from low-60% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $15k 5,673 shares | -100% | 0% from low-58% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $9,562 3,227 shares | -100% | 0% from low-54% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $5,541 1,700 shares | -100% | 0% from low-51% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $12k 3,555 shares | -100% | 0% from low-50% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $4,149 1,245 shares | -208% | +2% from low-48% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $23k 6,500 shares | -433% | +2% from low-40% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $23k 5,965 shares | -50% | +4% from low-38% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $2,105 535 shares | -100% | 0% from low-41% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $24k 6,500 shares | -100% | 0% from low-40% from high | |
| 5Weak | Randall Moreadith Chief Scientific Officer sell | $27k 6,500 shares | -100% | +2% from low-37% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $14k 3,398 shares | -100% | +5% from low-31% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $14k 3,102 shares | -100% | +5% from low-33% from high | |
| 5Weak | Randall Moreadith Chief Scientific Officer sell | $28k 5,551 shares | -100% | +24% from low-28% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $4,921 949 shares | -100% | +23% from low-29% from high | |
| 5Weak | Randall Moreadith Chief Scientific Officer sell | $32k 6,500 shares | -100% | +18% from low-37% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $22k 4,326 shares | -100% | +22% from low-37% from high | |
| 15Weak | Randall Moreadith Chief Scientific Officer sell | $331k 47,674 shares | -2335% | +37% from low-35% from high | |
| 0Weak | Randall Moreadith Chief Scientific Officer sell | $22k 4,304 shares | -193% | +27% from low-39% from high | |
| 5Weak | Randall Moreadith Chief Scientific Officer sell | $29k 5,500 shares | -100% | +33% from low-37% from high | |
| 5Weak | Randall Moreadith Chief Scientific Officer sell | $28k 5,500 shares | -100% | +25% from low-41% from high | |
| 5Weak | Randall Moreadith Chief Scientific Officer sell | $27k 4,196 shares | -100% | +45% from low-31% from high | |
| 26Weak | Randall Moreadith Chief Scientific Officer sell | $38k 6,500 shares | -100% | +39% from low-34% from high | |
| 26Weak | Randall Moreadith Chief Scientific Officer sell | $35k 6,500 shares | -100% | +30% from low-38% from high | |
| 26Weak | Randall Moreadith Chief Scientific Officer sell | $33k 6,500 shares | -100% | +25% from low-40% from high | |
| 6Weak | Randall Moreadith Chief Scientific Officer sell | $37k 6,500 shares | -100% | +35% from low-36% from high | |
| 6Weak | Randall Moreadith Chief Scientific Officer sell | $38k 6,500 shares | -100% | +50% from low-29% from high | |
| 18Weak | Gregory Bailey director buy | $18k 3,866 shares | +6% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 20, 2026 | Moreadith Randall Officer | 91,000 0.85% of outstanding | $279k | Jan 20, 2026 | $396k |
| Oct 14, 2025 | Moreadith Randall Officer | 88,826 0.87% of outstanding | $530k | Oct 13, 2025 | $543k |
| Jun 30, 2025 | Moreadith Randall Officer | 99,674 1.00% of outstanding | $576k | Jun 30, 2025 | none |
Transactions
The newest 50 of 171 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026 | Farrell Simon director | AGrant or award Stock Option (right to buy)derivative | +30,500 | $0.00 | $0 | 30,500 | Jul 23, 2026 |
| Jul 7, 2026 | Stephen K. Brannan director | POpen-market purchase Common Stock | +1,000 | $2.03 | $2,030 | 1,000 | Jul 9, 2026 |
| May 22, 2026 | Jay Venkatesan director | POpen-market purchase Common Stock | +589 | $1.78 | $1,048 | 589 | Jun 22, 2026 |
| Jun 17, 2026 | Stephen K. Brannan director | AGrant or award Stock Option (right to buy)derivative | +15,250 | $0.00 | $0 | 15,250 | Jun 22, 2026 |
| Jun 17, 2026 | Richard Peter Marshall director | AGrant or award Stock Option (right to buy)derivative | +15,250 | $0.00 | $0 | 15,250 | Jun 22, 2026 |
| Jun 17, 2026 | Gregory Bailey director | CConversion Common Stock | +1,770,805 | $2.25 | $4.0M | 1,897,445 | Jun 22, 2026 |
| Jun 17, 2026 | Gregory Bailey director | CConversion Common Stock | +6,666,667 | $2.25 | $15M | 8,564,382 | Jun 22, 2026 |
| Jun 17, 2026 | Karen J Wilson director | AGrant or award Stock Option (right to buy)derivative | +15,250 | $0.00 | $0 | 15,250 | Jun 22, 2026 |
| Jun 17, 2026 | Jay Venkatesan director | CConversion Common Stockindirect: The Jay Venkatesan Legacy Trust | +224,152 | $2.25 | $504k | 231,705 | Jun 22, 2026 |
| Jun 17, 2026 | Gregory Bailey director | AGrant or award Stock Option (right to buy)derivative | +15,250 | $0.00 | $0 | 15,250 | Jun 22, 2026 |
| Jun 17, 2026 | Jay Venkatesan director | AGrant or award Stock Option (right to buy)derivative | +15,250 | $0.00 | $0 | 15,250 | Jun 22, 2026 |
| Jun 17, 2026 | Gregory Bailey director | AGrant or award Redeemable Warrantsderivative | +3,333,333 | $0.00 | $0 | 3,333,333 | Jun 22, 2026 |
| Jun 17, 2026 | Jay Venkatesan director | CConversion Series A Convertible Preferred Stockderivativeindirect: The Jay Venkatesan Legacy Trust | -96,525 | $2.25 | $217k | 0 | Jun 22, 2026 |
| Jun 17, 2026 | Gregory Bailey director | CConversion Series A Convertible Preferred Stockderivative | -762,548 | $2.25 | $1.7M | 0 | Jun 22, 2026 |
| Jun 11, 2026 | Karen J Wilson director | POpen-market purchase Common Stock | +5,100 | $1.75 | $8,900 | 5,100 | Jun 15, 2026 |
| Jun 12, 2026 | Karen J Wilson director | POpen-market purchase Common Stock | +5,000 | $1.77 | $8,850 | 10,100 | Jun 15, 2026 |
| May 26, 2026 | Steven A Ledger Chief Executive Officer | AGrant or award Common Stock | +10,100 | $1.93 | $19k | 10,100 | May 27, 2026 |
| May 21, 2026 | Gregory S Curhan Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +123,019 | $0.00 | $0 | 123,019 | May 26, 2026 |
| May 21, 2026 | Steven A Ledger Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +380,825 | $0.00 | $0 | 380,825 | May 26, 2026 |
| May 21, 2026 | Randall Moreadith Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +85,558 | $0.00 | $0 | 85,558 | May 26, 2026 |
| May 21, 2026 | Karen J Wilson director | POpen-market purchase Common Stock | +10,000 | $1.77 | $18k | 10,000 | May 26, 2026 |
| May 21, 2026 | Srini Tenjarla SVP, CMC & Formulation | AGrant or award Stock Option (right to buy)derivative | +85,558 | $0.00 | $0 | 85,558 | May 26, 2026 |
| May 22, 2026 | Karen J Wilson director | POpen-market purchase Common Stock | +10,000 | $1.93 | $19k | 20,000 | May 26, 2026 |
| May 19, 2026 | Richard Peter Marshall director | POpen-market purchase Common Stock | +12,183 | $1.65 | $20k | 12,183 | May 22, 2026 |
| Mar 31, 2026 | Gregory Bailey director | AGrant or award Common Stock | +59,667 | $1.94 | $116k | 126,910 | Apr 21, 2026 |
| Mar 31, 2026 | Jay Venkatesan director | AGrant or award Common Stock | +7,553 | $1.94 | $15k | 7,553 | Apr 21, 2026 |
| Mar 23, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +6,500 | $0.06 | $390 | 6,500 | Mar 24, 2026 |
| Mar 23, 2026 | Randall Moreadith Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -6,500 | $2.86 | $19k | 0 | Mar 24, 2026 |
| Mar 23, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,500 | $0.00 | $0 | 267,686 | Mar 24, 2026 |
| Mar 19, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +39,000 | $0.06 | $2,340 | 39,000 | Mar 20, 2026 |
| Mar 19, 2026 | Randall Moreadith Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -39,000 | $2.50 | $98k | 0 | Mar 20, 2026 |
| Mar 19, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -39,000 | $0.00 | $0 | 274,186 | Mar 20, 2026 |
| Feb 3, 2026 | Simba Gill director | AGrant or award Stock Option (right to buy)derivative | +92,000 | $0.00 | $0 | 92,000 | Feb 17, 2026 |
| Feb 3, 2026 | Steven A Ledger Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +230,100 | $0.00 | $0 | 230,100 | Feb 17, 2026 |
| Feb 3, 2026 | Randall Moreadith Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +69,000 | $0.00 | $0 | 69,000 | Feb 17, 2026 |
| Feb 3, 2026 | Srini Tenjarla SVP, CMC & Formulation | AGrant or award Stock Option (right to buy)derivative | +69,000 | $0.00 | $0 | 69,000 | Feb 17, 2026 |
| Feb 2, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +6,500 | $0.06 | $390 | 6,500 | Feb 3, 2026 |
| Feb 2, 2026 | Randall Moreadith Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -6,500 | $3.03 | $20k | 0 | Feb 3, 2026 |
| Feb 2, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,500 | $0.00 | $0 | 313,186 | Feb 3, 2026 |
| Jan 28, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +6,500 | $0.06 | $390 | 6,500 | Jan 29, 2026 |
| Jan 28, 2026 | Randall Moreadith Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -6,500 | $3.57 | $23k | 0 | Jan 29, 2026 |
| Jan 28, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,500 | $0.00 | $0 | 319,686 | Jan 29, 2026 |
| Jan 22, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +2,500 | $0.06 | $150 | 2,500 | Jan 23, 2026 |
| Jan 22, 2026 | Randall Moreadith Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,500 | $2.95 | $7,375 | 0 | Jan 23, 2026 |
| Jan 22, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,500 | $0.00 | $0 | 326,186 | Jan 23, 2026 |
| Jan 20, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +2,000 | $0.06 | $120 | 2,000 | Jan 21, 2026 |
| Jan 20, 2026 | Randall Moreadith Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,000 | $3.07 | $6,140 | 0 | Jan 21, 2026 |
| Jan 21, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +2,000 | $0.06 | $120 | 2,000 | Jan 21, 2026 |
| Jan 21, 2026 | Randall Moreadith Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,000 | $3.00 | $6,000 | 0 | Jan 21, 2026 |
| Jan 20, 2026 | Randall Moreadith Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 330,686 | Jan 21, 2026 |
50 of 171 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Gregory Baileydirector
- Stephen K. Brannandirector, officer
- Gregory S CurhanChief Financial Officer
- Simba Gilldirector, ceo, president, officer
- Steven A LedgerChief Executive Officer
- Richard Peter Marshalldirector
- Randall MoreadithChief Scientific Officer
- Farrell Simonofficer, director
- Srini TenjarlaSVP, CMC & Formulation
- Jay Venkatesandirector
- Karen J Wilsondirector
Questions about SER
Answered from the filings on this page, as of the latest one.
Are insiders buying SER?
No. In the last 90 days no insider at Serina Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SER on the open market?
Stephen K. Brannan (director) bought $2,030 of SER on Jul 7, 2026 and filed the Form 4 on Jul 9, 2026. InsiderTell scored 31 (weak).
How many insiders file Form 4 at Serina Therapeutics, Inc.?
11 people have filed a Form 4 at Serina Therapeutics, Inc., among them Gregory Bailey (director), Stephen K. Brannan (director and officer), Gregory S Curhan (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.